Hepatitis C medical therapy
|
Hepatitis C |
|
Diagnosis |
|
Treatment |
|
Hepatitis C medical therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis C medical therapy |
|
Risk calculators and risk factors for Hepatitis C medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Nina Axiotakis [2]
Treatment
Treatment during the acute infection phase has much higher success rates (greater than 90%) with a shorter duration of treatment (but balance this against the 80% chance of spontaneous clearance without treatment).
Those with low initial viral loads respond much better to treatment than those with higher viral loads (greater than 2 million virons/ml). Current combination therapy is usually supervised by physicians in the fields of gastroenterology, hepatology or infectious disease.
The treatment may be physically demanding, particularly those with a prior history of drug or alcohol abuse. It can qualify for temporary disability in some cases. A substantial proportion of patients will experience a panoply of side effects ranging from a 'flu-like' syndrome (the most common, experienced for a few days after the weekly injection of interferon) to severe adverse events including anemia, cardiovascular events and psychiatric problems such as suicide or suicidal ideation. The latter are exacerbated by the general physiological stress experienced by the patient.
In addition to the standard treatment with interferon and ribavirin, some studies have shown a higher success rates when the antiviral drug amantadine (Symmetrel) is added to the regimen. Sometimes called "triple therapy", it involves the addition of 100mg of amantadine twice a day. Studies indicate that this may be especially helpful for "nonresponders" - patients who have not been successful in previous treatments using interferon and ribavirin only.[1] Currently, amantadine is not approved for treatment of Hepatitis C, and studies are ongoing to determine when it is most likely to benefit the patient. Followup studies have shown no benefit to adding this drug and currently it is not commonly used by experienced hepatologists.
Current guidelines strongly recommend that hepatitis C patients be vaccinated for hepatitis A and B if they have not yet been exposed to these viruses, as this would radically worsen their liver disease.
Alcoholic beverage consumption accelerates HCV associated fibrosis and cirrhosis, and makes liver cancer more likely; insulin resistance and metabolic syndrome may similarly worsen the hepatic prognosis. There is also evidence that smoking increases the fibrosis (scarring) rate.
Treatment Indications
- Clearly Indicated
- Detectable HCV RNA and persistently elevated alanine aminotransferase (ALT)
- Liver biopsy with fibrosis or moderate necrosis/inflammation
- High risk disease progression
- Possibly Beneficial
- Detectable HCV RNA and elevated ALT
- Liver biopsy with minimal or mild inflammatory changes
- Lower risk disease progression
- Alternative = follow ALT and re-biopsy at 3-5 years
- Not Indicated
- Detectable HCV RNA with persistently normal ALT
- Liver biopsy with minimal or no inflammatory changes
- Excellent prognosis without therapy
- May consider therapy if extrahepatic hepatic manifestations
- Contraindicated
- IFN-alfa
- Severe depression, psychosis
- Decompensated cirrhosis
- Neutropenia or thrombocytopenia
- Uncontrolled seizures
- Organ transplant (other than liver)
- Symptomatic heart disease
- Ribavirin
- Pregnancy or inadequate contraception
- Anemia, hemoglobinopathy
- Severe cardiac disease or end-stage renal disease (ESRD)
- IFN-alfa
Chronic Pharmacotherapies
- Interferon alfa monoRx
- Sustained response 16%
- Genotype 1a or 1b--lowest response rate
- IFN-alfa + ribavirin
- Sustained response 40%
- Genotype 1 or high HCV RNA--max response at 48 weeks
- Genotype 2 or 3--maximal response at 24 weeks
- Doses = IFN 3 mU sc tiw + ribavirin 600 mg po bid
- If HCV RNA+ at 24 weeks, discontinue therapy (no response)
- Pegylated Interferon
- Higher response rate than conventional IFN monoRx
- Weight-based dose given every week
- Combination with ribavirin currently in clinical trials
During pregnancy and breastfeeding
If a pregnant woman has risk factors for hepatitis C, she should be tested for antibodies against HCV. About four out of every hundred infants born to HCV infected women become infected. The virus is spread to the baby at the time of birth. There is no treatment that can prevent this from happening.
In a mother that also has HIV, the rate of transmission can be as high as 19%. There is currently no data to determine whether antiviral therapy reduces perinatal transmission. Ribavirin and interferons are contraindicated during pregnancy. However, avoiding fetal scalp monitoring and prolonged labor after rupture of membranes may reduce the risk of transmission to the infant.
HCV antibodies from the mother may persist in infants until 15 months of age. If an early diagnosis is desired, testing for HCV RNA can be performed between the ages of 2 and 6 months, with a repeat test done independent of the first test result. If a later diagnosis is preferred, an anti-HCV test can performed after 15 months of age. Most infants infected with HCV at the time of birth have no symptoms and do well during childhood. There is no evidence that breast-feeding spreads HCV. To be cautious, an infected mother should avoid breastfeeding if her nipples are cracked and bleeding.[2]
References
- ↑ Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed S, Adeleine P, Trépo C (2006). "Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)". J Hepatol. 44 (3): 484–90. PMID 16426697.
- ↑ Mast E. "Mother-to-infant hepatitis C virus transmission and breastfeeding". Adv Exp Med Biol. 554: 211–6. PMID 15384578.